Is Biotech Stock the Future of Our Economy?

Biotech is doing well right now, unlike most industries in these incredibly difficult circumstances.

Executives in numerous other industries are growing more worried about the future of their companies as the worldwide epidemic spreads.

Though the tremendous government, media, and public attention has focused on science and medicine in the quest to comprehend and find a cure or preventive measures for COVID-19, this has only strengthened the public's belief that biotech collaborations and acquisitions are wise investments.

Numerous biotech stocks, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a new bull market despite the struggling stock market.

The Growth Factor

The unexpected success of biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability. Big Pharma company acquisitions, robust earnings, and a favorable regulatory environment have all contributed to the comeback in biotech stock prices.

And more fuel is added by the alluring possibility of positive CRISPR gene editing news later this year. The sector ranks seventh for price performance in recent months out of the 197 industries tracked by Investor's Business Daily, even though biotech stocks have somewhat retreated recently, and a further ascent isn't guaranteed. This is where cell culture process development comes into the picture.

Biotech stock – A force to reckon with

The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the industry has been propelled by the top biotech stocks, placing eighth overall with a Relative Strength Rating of 96. Regarding six-month performance, the group is in the top 4% of all industries.

Edison research indicates that groups who begin to exhibit strength in the latter stages of a bad market frequently steer the following bull market. A few biotech stocks are also poised for significant gains. They include Catalyst Pharmaceuticals (CPRX), the top-rated biotech stock, which is anticipated to post its highest-ever profits in 2022–2023. Since July, Catalyst share prices have more than doubled.

There Is No Stopping The Biotech Train

This year and the following are projected to see the catalysts around biotech stocks persist. According to RBC analyst Gregory Renza, investors focused on the Alnylam, Karuna, and Seagen data announcements earlier this year.

In the second half of 2022 and early 2023, analysts typically predict a string of smaller catalysts to dominate the market rather than a single large catalyst. Lecanemab, a potential treatment for Alzheimer's, is scheduled to receive additional test findings from Biogen (BIIB) and Eisai.

Positive news for lecanemab could give the biotech stock a much-needed boost after Biogen's Aduhelm failure, which saw the Food and Drug Administration approve it. Still, the Centers for Medicare and Medicaid Services largely decline to cover it. Roche (RHHBY) is testing a comparable medication.

For the first time since the Covid vaccinations and hepatitis C medications, an Alzheimer's disease breakthrough may open up a mostly untapped $15 billion market for biopharma, according to RBC analysts in research. Additionally, a successful outcome's enthusiasm could draw fresh money back into the space.